NPPB and myocardial infarction: A secondary analysis of the PLATelet inhibition and patient Outcomes (PLATO) biomarker study on 17,905 patients presenting with ACS (37.6% with ST-segment elevation myocardial infarction) showed that NT-proBNP levels measured at a median of 10 h after admission was the strongest marker of all-cause mortality, death due to MI, and sudden cardiac death/arrhythmia [9].